DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes).
Accessed June 15, 2021 at:
https://ClinicalTrials.gov/show/NCT02993406
We do not assume any responsibility for the contents of the web pages of other providers.